SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mark Adams who wrote (12099)2/22/2001 4:27:58 PM
From: TimbaBear  Read Replies (2) of 78470
 
I'll wait and do an updated analysis on CEGE when the new 10Q is filed. Like I said in my previous post on this issue, there will be tax benefits from writing down the value of marketable securities and I want to see the net impact before changing anything. Remember that this is a research company and will often have losses because of that. As of the last 10Q CEGE was FCF positive. I think there is huge value in their cancer vaccines that are in various stages of clinical trials.

I'll play the short advocate on IDTC. To me, they have a negative NetNet value of -$3.04/share. I don't buy companies with negative NetNet value, especially in a hostile market. Although they show a positive net income on the income statement, when non-cash and non-operational revenues and costs are adjusted for, they are FCF negative. So they are losing money at what they do, and have a negative NetNet worth. In this time of so many stocks getting hammered, I think there are better, safer, employments of investment capital for my dollar.

All of this is one person's opinion and no investment decisions should be based on that opinion because it could be totally incorrect as it is not prepared by a professionally trained investment analyst.

Timba
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext